132 related articles for article (PubMed ID: 33244872)
1. Human plasma-derived alpha
Lagarde WH; Courtney KL; Reiner B; Steinmann K; Tsalikian E; Willi SM
Pediatr Diabetes; 2021 Mar; 22(2):192-201. PubMed ID: 33244872
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).
Campos MA; Kueppers F; Stocks JM; Strange C; Chen J; Griffin R; Wang-Smith L; Brantly ML
COPD; 2013 Dec; 10(6):687-95. PubMed ID: 23862647
[TBL] [Abstract][Full Text] [Related]
3. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of Alpha-1 MP (Prolastin
Seyama K; Nukiwa T; Sato T; Suzuki M; Konno S; Takahashi K; Nishimura M; Steinmann K; Sorrells S; Chen J; Hayashi KI
Respir Investig; 2019 Jan; 57(1):89-96. PubMed ID: 30416054
[TBL] [Abstract][Full Text] [Related]
5. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.
Stocks JM; Brantly M; Pollock D; Barker A; Kueppers F; Strange C; Donohue JF; Sandhaus R
COPD; 2006 Mar; 3(1):17-23. PubMed ID: 17175661
[TBL] [Abstract][Full Text] [Related]
6. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.
Gaggar A; Chen J; Chmiel JF; Dorkin HL; Flume PA; Griffin R; Nichols D; Donaldson SH
J Cyst Fibros; 2016 Mar; 15(2):227-33. PubMed ID: 26321218
[TBL] [Abstract][Full Text] [Related]
7. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia
Lebenthal Y; Brener A; Hershkovitz E; Shehadeh N; Shalitin S; Lewis EC; Elias D; Haim A; Barash G; Loewenthal N; Zuckerman-Levin N; Stein M; Tov N; Rachmiel M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795482
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency.
Barker AF; Iwata-Morgan I; Oveson L; Roussel R
Chest; 1997 Sep; 112(3):607-13. PubMed ID: 9315791
[TBL] [Abstract][Full Text] [Related]
9. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices.
Brand P; Beckmann H; Maas Enriquez M; Meyer T; Müllinger B; Sommerer K; Weber N; Weuthen T; Scheuch G
Eur Respir J; 2003 Aug; 22(2):263-7. PubMed ID: 12952258
[TBL] [Abstract][Full Text] [Related]
10. Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
Weir GC; Ehlers MR; Harris KM; Kanaparthi S; Long A; Phippard D; Weiner LJ; Jepson B; McNamara JG; Koulmanda M; Strom TB;
Pediatr Diabetes; 2018 Aug; 19(5):945-954. PubMed ID: 29473705
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of a Liquid Formulation of Alpha
Barker AF; Campos MA; Brantly ML; Stocks JM; Sandhaus RA; Lee D; Steinmann K; Lin J; Sorrells S
COPD; 2017 Dec; 14(6):590-596. PubMed ID: 28985109
[TBL] [Abstract][Full Text] [Related]
12. Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus.
Rachmiel M; Strauss P; Dror N; Benzaquen H; Horesh O; Tov N; Weintrob N; Landau Z; Ben-Ami M; Haim A; Phillip M; Bistritzer T; Lewis EC; Lebenthal Y
Pediatr Diabetes; 2016 Aug; 17(5):351-9. PubMed ID: 26073583
[TBL] [Abstract][Full Text] [Related]
13. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Gitelman SE; Gottlieb PA; Rigby MR; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; Ding L; Bluestone JA; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):306-16. PubMed ID: 24622416
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Stocks JM; Brantly ML; Wang-Smith L; Campos MA; Chapman KR; Kueppers F; Sandhaus RA; Strange C; Turino G
BMC Clin Pharmacol; 2010 Sep; 10():13. PubMed ID: 20920295
[TBL] [Abstract][Full Text] [Related]
16. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
17. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
[TBL] [Abstract][Full Text] [Related]
18. Proinsulin to C-Peptide Ratio in the First Year After Diagnosis of Type 1 Diabetes.
Freese J; Al-Rawi R; Choat H; Martin A; Lunsford A; Tse H; Mick G; McCormick K
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4318-e4326. PubMed ID: 34228132
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
[TBL] [Abstract][Full Text] [Related]
20. Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI[H]) Inhalation Solution Using Two Inhalation Modes of the I-neb Adaptive Aerosol Delivery (AAD) System in Healthy Subjects and Subjects with Cystic Fibrosis.
Häussermann S; Winnips C; Edelman J; Kappeler D; Herpich C; Ehlich H; Zanker D; Kietzig C; Sommerer K
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):242-50. PubMed ID: 26669827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
